A 54-year-old Cambodian was diagnosed with early-stage lung cancer during a routine health check-up and successfully treated ...

Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.

Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility ...

FDA clears perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, boosting event-free and overall survival ahead of cystectomy. The FDA has approved pembrolizumab ...

After giving birth to her second child in July 2024, Mayya Grinberg expected the sleepless nights and exhaustion that often come with caring for a newborn. But what she didn't expect was the nagging ...

NEW ORLEANS -- More extensive N1 lymph node assessment may better guide therapy after non-small cell lung cancer (NSCLC) resections with curative intent, real-world data suggested. The more N1 ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node evaluation is needed during surgery for non-small cell lung cancer (NSCLC) to ...

Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non–small cell lung cancer. We aimed to investigate whether no mediastinal LND was ...

For patients with early-stage cervical cancer, sentinel lymph node biopsy alone is noninferior to lymphadenectomy with respect to disease-free survival, according to a study published online Oct. 15 ...

Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer. In this multicenter, randomized, noninferiority trial, we ...

The prognosis of patients with lung cancer and interstitial lung disease (ILD) is worse than that of patients without ILDs; however, therapeutic options for ILD-associated lung cancer are severely ...